| pubmed-article:8205089 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8205089 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8205089 | lifeskim:mentions | umls-concept:C0005961 | lld:lifeskim |
| pubmed-article:8205089 | lifeskim:mentions | umls-concept:C0023473 | lld:lifeskim |
| pubmed-article:8205089 | lifeskim:mentions | umls-concept:C0006463 | lld:lifeskim |
| pubmed-article:8205089 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:8205089 | lifeskim:mentions | umls-concept:C1521827 | lld:lifeskim |
| pubmed-article:8205089 | lifeskim:mentions | umls-concept:C1515895 | lld:lifeskim |
| pubmed-article:8205089 | lifeskim:mentions | umls-concept:C0457343 | lld:lifeskim |
| pubmed-article:8205089 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:8205089 | pubmed:dateCreated | 1994-7-8 | lld:pubmed |
| pubmed-article:8205089 | pubmed:abstractText | Thirty-four patients with chronic myelogenous leukemia in chronic phase were treated with busulfan 16 mg/kg and cyclophosphamide 120 or 200 mg/kg before allogeneic bone marrow transplantation from an HLA-identical sibling. Cyclosporine, methotrexate and prednisone were used for graft-versus-host disease (GVHD) prophylaxis. The actuarial probabilities of survival and relapse-free survival at 82 months were 71%. With a maximum follow-up of 2471 days, none of the patient experienced hematologic or clinical relapse. In one patient reappearance of host cells was documented 180 days post-transplant which disappeared 277 days post-transplant and the patient is in complete hematological and cytogenetic remission 5 years after the transplant. The probability of transplant-related mortality was 29% while the probability of moderate to severe acute graft-versus-host disease was 38%. This study indicates that busulfan and cyclophosphamide are a good conditioning regimen for marrow transplantation in patients with chronic myeloid leukemia in chronic phase. | lld:pubmed |
| pubmed-article:8205089 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8205089 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8205089 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8205089 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8205089 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8205089 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8205089 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8205089 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8205089 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8205089 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:8205089 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:8205089 | pubmed:author | pubmed-author:LucarelliGG | lld:pubmed |
| pubmed-article:8205089 | pubmed:author | pubmed-author:PolchiPP | lld:pubmed |
| pubmed-article:8205089 | pubmed:author | pubmed-author:ErenNN | lld:pubmed |
| pubmed-article:8205089 | pubmed:author | pubmed-author:BaroncianiDD | lld:pubmed |
| pubmed-article:8205089 | pubmed:author | pubmed-author:GalimbertiMM | lld:pubmed |
| pubmed-article:8205089 | pubmed:author | pubmed-author:GiardiniCC | lld:pubmed |
| pubmed-article:8205089 | pubmed:author | pubmed-author:AngelucciEE | lld:pubmed |
| pubmed-article:8205089 | pubmed:author | pubmed-author:RapsAA | lld:pubmed |
| pubmed-article:8205089 | pubmed:author | pubmed-author:GazievDD | lld:pubmed |
| pubmed-article:8205089 | pubmed:author | pubmed-author:RipaltiMM | lld:pubmed |
| pubmed-article:8205089 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8205089 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:8205089 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8205089 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:8205089 | pubmed:pagination | 197-201 | lld:pubmed |
| pubmed-article:8205089 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:8205089 | pubmed:meshHeading | pubmed-meshheading:8205089-... | lld:pubmed |
| pubmed-article:8205089 | pubmed:meshHeading | pubmed-meshheading:8205089-... | lld:pubmed |
| pubmed-article:8205089 | pubmed:meshHeading | pubmed-meshheading:8205089-... | lld:pubmed |
| pubmed-article:8205089 | pubmed:meshHeading | pubmed-meshheading:8205089-... | lld:pubmed |
| pubmed-article:8205089 | pubmed:meshHeading | pubmed-meshheading:8205089-... | lld:pubmed |
| pubmed-article:8205089 | pubmed:meshHeading | pubmed-meshheading:8205089-... | lld:pubmed |
| pubmed-article:8205089 | pubmed:meshHeading | pubmed-meshheading:8205089-... | lld:pubmed |
| pubmed-article:8205089 | pubmed:meshHeading | pubmed-meshheading:8205089-... | lld:pubmed |
| pubmed-article:8205089 | pubmed:meshHeading | pubmed-meshheading:8205089-... | lld:pubmed |
| pubmed-article:8205089 | pubmed:meshHeading | pubmed-meshheading:8205089-... | lld:pubmed |
| pubmed-article:8205089 | pubmed:meshHeading | pubmed-meshheading:8205089-... | lld:pubmed |
| pubmed-article:8205089 | pubmed:meshHeading | pubmed-meshheading:8205089-... | lld:pubmed |
| pubmed-article:8205089 | pubmed:meshHeading | pubmed-meshheading:8205089-... | lld:pubmed |
| pubmed-article:8205089 | pubmed:meshHeading | pubmed-meshheading:8205089-... | lld:pubmed |
| pubmed-article:8205089 | pubmed:meshHeading | pubmed-meshheading:8205089-... | lld:pubmed |
| pubmed-article:8205089 | pubmed:meshHeading | pubmed-meshheading:8205089-... | lld:pubmed |
| pubmed-article:8205089 | pubmed:meshHeading | pubmed-meshheading:8205089-... | lld:pubmed |
| pubmed-article:8205089 | pubmed:meshHeading | pubmed-meshheading:8205089-... | lld:pubmed |
| pubmed-article:8205089 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8205089 | pubmed:articleTitle | Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide. | lld:pubmed |
| pubmed-article:8205089 | pubmed:affiliation | Divisione di Ematologia, Ospedale di Pesaro, Italy. | lld:pubmed |
| pubmed-article:8205089 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8205089 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8205089 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
